Plain-English translation of NCT05641428 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether CAR T-cell therapy produced quickly in your local hospital works as well as the standard version made at commercial facilities. CAR T-cell therapy is a personalized cancer treatment where doctors take your own immune cells, reprogram them in a lab to fight lymphoma, and put them back into your body. The research team believes that making these cells faster and fresher—without freezing and shipping them—might work better for patients whose lymphoma has stopped responding to other treatments.
Currently, making this medication takes about 4 weeks at a commercial facility, and the cells must be frozen twice during shipping, which can damage them. This delay means some patients with fast-growing lymphoma don't survive long enough to receive their treatment. This trial is testing whether making the cells locally in 7–12 days and using them fresh could be faster, work better, and help more patients.
You likely qualify if…
You likely don't qualify if…
First, your doctors will collect your own immune cells through a process similar to a blood draw. Your cells will be sent to the laboratory at your hospital, where they will be reprogrammed over 7–12 days. You will receive chemotherapy to prepare your body, and then the treatment cells will be infused back into you. You'll be monitored closely for side effects and your response to the treatment over several months. The entire process, from cell collection to infusion, takes a few weeks.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Netherlands